[Retracted] Effect of PARP Inhibitor Combined with Bevacizumab on Platinum-Resistant Recurrent Ovarian Epithelial Carcinoma

Table 7

Comparison of survival time between the two groups [cases (%)].

Group	Follow-up of 1 year		Follow-up of 2 years		Follow-up of 3 years
	Survival	Death	Survival	Death	Survival	Death
Observation group ()	41 (97.62)	1 (2.38)	37 (88.10)	5 (11.90)	34 (80.95)	8 (19.05)
Control group ()	30 (71.43)	12 (28.57)	24 (57.14)	18 (42.86)	20 (47.62)	22 (52.38)
Log-rank	10.860		10.830		11.370
	0.001		0.001		0.001